Company: CRL
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001100682-25-000043
Chunk: 10

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 4
Chunk 10
---
 may also be disruptive to our business operations and long-term planning, which may cause concern to our current or potential investors, customers, employees, strategic partners, vendors and other stakeholders and may have a material impact on our operating results or result in increased volatility in our stock price. 

Any potential transaction or other strategic alternative would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, regulatory approvals, and the availability of financing for a potential transaction on favorable terms. There can be no assurance that any potential transaction or other strategic alternative will be successfully implemented, achieve the intended benefits or provide greater value to our stockholders than that reflected in the current price of our common stock. Until the review process is concluded, perceived uncertainties related to our future may result in the loss of potential business opportunities, volatility in the market price of our common stock and difficulty attracting and retaining qualified talent and business partners.

42 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information relating to the purchases of shares of our common stock during the three months ended September 27, 2025.Total Numberof SharesPurchasedAveragePrice Paidper ShareTotal Number ofShares Purchasedas Part of PubliclyAnnounced Plansor ProgramsApproximate DollarValue of SharesThat May Yet BePurchased Underthe Plans or Programs(in thousands)June 29, 2025 to July 26, 2025182 $152.20 — $549,285 July 27, 2025 to August 23, 2025265 169.64 — 549,285 August 24, 2025 to September 27, 2025130 162.82 — 549,285 Total577  —  

Through September 27, 2025 our Board of Directors had authorized up to $1.0 billion for our stock repurchase program. During the three months ended September 27, 2025, we did not repurchase any shares of common stock under our stock repurchase program or in open market trading. As of September 27, 2025, we had $549.3 million remaining on the authorized stock repurchase program.

On October 29, 2025, our Board of Directors approved a new stock repurchase authorization of $1.0 billion. This new authorization replaces the prior stock